Pharsight Releases Drug Model Explorer Version 1.6
Feature Improvements Extend Use of Product Profiles, Enhance Display of Model-Based Success Predictions Versus Competing Treatments
NEW YORK, July 20, 2007--Pharsight Corporation (OTC Bulletin Board:
PHST), a leading provider of software and strategic services for
optimizing clinical drug development, today announced the release
of Drug Model Explorer (DMX(r)) version 1.6. The new release
supports improved visualizations of predicted drug performance
against user-defined target measures of clinical safety and
efficacy that collectively define a product profile.
DMX is a web-based and desktop software tool that allows clinical drug development teams to quickly and efficiently explore the modeled efficacy, safety, and other performance attributes of a new drug versus competing therapies.
The DMX 1.6 release displays the chance that a modeled drug effect will meet a specific target profile, through additions to the software interface that present probabilistic results more prominently to support clinical development decision-making. DMX 1.6 provides the ability to create, explore, compare and manage product profiles, using existing DMX data and functionality in combination with new profiles features.
DMX 1.6 continues to support the full set of end-user features
available in previous releases, and adds support for Oracle(r)
database version 10g and Internet Explorer version 7.0. DMX 1.6
also provides an updated user interface for the desktop viewing
application to provide the same look and feel as the web-based
viewer.
"DMX's intuitive presentation of model-based product profiles is especially powerful when a new drug faces tough competition," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "The new release makes competitive product profiles a central aspect of the interface so drug development teams and decision-makers can interact with model-based results in a familiar context. FDA's recent draft guidance on target product profiles as a strategic communication tool, and continued advocacy of model-based drug development to support its Critical Path Initiative, reinforces our expectation that profile-based DMX results have value to advance the use of quantitative modeling and simulation. We continue to work closely with our customers to meet their emerging technology needs, and look forward to receiving early feedback from the field on this latest DMX release."
About DMX
DMX is a software visualization and communication tool to explore model-based results of a compound's product profile. Through the DMX interface the development team can address key strategic development questions by comparing probabilistic outcomes for different endpoints, treatment strategies, and patient populations against competing products. DMX results are presented as a series of plots and tables that can be quickly updated based on pre-simulated models of clinical effect. Results are accessible from networked desktop or laptop computers for individual exploration, interactive team discussion, and communication of development strategies and program alternatives with senior decision-makers. Pharsight believes that DMX will help increase the usage of quantitative-based decision-making in the drug development process.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug
development success: strong decision-making. By adopting the
Pharsight approach, customers acquire a new decision-making process
with the potential to systematically improve every level and phase
of their business and scientific processes. Pharsight is
headquartered in Mountain View, California.
Forward Looking Statements
The statements in this press release related to the design and performance of the Pharsight Drug Model Explorer product are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: changes in FDA regulations may affect the demand for Drug Model Explorer; and customers may not perceive the benefits of the product to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10-K filed with the Securities and Exchange Commission on June 27, 2007. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements
Jen Saunders
Senior Account Executive
EVC Group
60 East 42nd Street
Suite 936
New York, NY 10165
646.201.5431 direct
917.514.6512 cell
212.661.0035 fax
jsaunders@evcgroup.com
Posted: July 2007
